EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme

Video
Conference|EURETINA

Dara Conlon, Executive Vice President of EURETINA, and Prof. Anat Loewenstein, General Secretary of EURETINA, discuss some key features of this year's Congress.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A scientist in a lab looks into a microscope, which is placed on a desk. His face is not fully visible but he wears a lab coat and sits in front of a computer. Concept image for cell therapy, stem cell research, phase 1 clinical trial, and geographic atrophy associated with age-related macular degeneration. Image credit: ©CoetzeeRising/peopleimages.com – stock.adobe.com

Eyestem Research announces positive results from phase 1 geographic atrophy trial

Martin David Harp
April 14th 2025
Article

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A syringe and containers of liquid in front of the European Medicines Agency logo. Concept image for aflibercept Eylea EMA approval. Image credit: ©SoniaBonet – stock.adobe.com

Bayer submits EMA application for aflibercept 8mg third indication, retinal vein occlusion

Hattie Hayes
April 9th 2025
Article

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A photo of the United States Food and Drug Administration FDA headquarters. Concept image for FDA ophthalmic presbyopia treatment application submission. Image credit: ©Tada Images – stock.adobe.com

Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF

Jordana Joy
April 8th 2025
Article

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026

A person stands among a field of numbers representing binary code and a search through data. Concept image for artificial intelligence. Image credit: ©Creativa Images – stock.adobe.com

A real-world study of an AI system for enhanced detection of diabetic retinopathy

Lynda Charters
April 7th 2025
Article

Fundus images of diabetic retinopathy were assessed by general ophthalmologists, retina specialists and the Aireen artificial intelligence system

© 2025 MJH Life Sciences

All rights reserved.